UY32177A - Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético - Google Patents
Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabéticoInfo
- Publication number
- UY32177A UY32177A UY0001032177A UY32177A UY32177A UY 32177 A UY32177 A UY 32177A UY 0001032177 A UY0001032177 A UY 0001032177A UY 32177 A UY32177 A UY 32177A UY 32177 A UY32177 A UY 32177A
- Authority
- UY
- Uruguay
- Prior art keywords
- oral
- patients
- diabetes
- insufficient
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La presente invención se refiere al descubrimiento de que determinados inhibidores de DPP-4 son particularmente adecuados para tratar y/o prevenir enfermedades metabólicas, en particular la diabetes, en pacientes con control glucémico insuficiente a pasar de una terapia con un fármaco antidiabético oral y/o no oral.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10591908P | 2008-10-16 | 2008-10-16 | |
EP08166829 | 2008-10-16 | ||
EP09167304 | 2009-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32177A true UY32177A (es) | 2010-05-31 |
Family
ID=41426834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032177A UY32177A (es) | 2008-10-16 | 2009-10-14 | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético |
Country Status (20)
Country | Link |
---|---|
US (3) | US20110275561A1 (es) |
EP (2) | EP2349240A1 (es) |
JP (5) | JP2012505859A (es) |
KR (6) | KR20240046643A (es) |
CN (3) | CN109700814A (es) |
AR (1) | AR073876A1 (es) |
AU (1) | AU2009305419B2 (es) |
CA (1) | CA2738367C (es) |
CO (1) | CO6361917A2 (es) |
EA (1) | EA026810B1 (es) |
EC (1) | ECSP11010971A (es) |
IL (1) | IL211370A0 (es) |
MA (1) | MA32872B1 (es) |
MX (3) | MX2011003774A (es) |
NZ (2) | NZ605207A (es) |
PE (1) | PE20110396A1 (es) |
TN (1) | TN2011000176A1 (es) |
TW (1) | TWI520738B (es) |
UY (1) | UY32177A (es) |
WO (1) | WO2010043688A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
CN102037121B (zh) | 2008-03-26 | 2013-07-10 | 奥拉姆德有限公司 | 用于口服给予蛋白质的方法和组合物 |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
CN107011345A (zh) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | 有机化合物的盐形式 |
AR074990A1 (es) * | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
EP3646859A1 (en) | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
EP2566464A1 (en) * | 2010-05-05 | 2013-03-13 | Boehringer Ingelheim International GmbH | Pharmaceutical formulations comprising pioglitazone and linagliptin |
AU2011249722B2 (en) | 2010-05-05 | 2015-09-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
BR112012032579B1 (pt) * | 2010-06-24 | 2021-05-11 | Boehringer Ingelheim International Gmbh | uso de linagliptina e composição farmacêutica compreendendo linagliptina e insulina basal de longa duração |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
AU2016202261B2 (en) * | 2010-11-15 | 2017-11-30 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
HUE043540T2 (hu) | 2011-07-15 | 2019-08-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171166A1 (en) * | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
EP2854812A1 (en) * | 2012-05-24 | 2015-04-08 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP2941267B1 (en) | 2013-01-03 | 2022-11-16 | Oramed Ltd. | Compositions for use in treating nafld |
JP2016510795A (ja) * | 2013-03-15 | 2016-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用 |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
TWI682931B (zh) * | 2015-05-29 | 2020-01-21 | 大陸商江蘇天士力帝益藥業有限公司 | 黃嘌呤衍生物、其藥物組成物、其製劑以及其用途 |
JP7042755B2 (ja) | 2016-06-05 | 2022-03-28 | バーグ エルエルシー | 患者層別化及び潜在的バイオマーカー同定のためのシステム及び方法 |
BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060034922A1 (en) * | 2000-11-03 | 2006-02-16 | Andrx Labs, Llc | Controlled release metformin compositions |
US7610153B2 (en) * | 2002-02-13 | 2009-10-27 | Virginia Commonwealth University | Multi-drug titration and evaluation |
EP2070539A1 (de) * | 2002-08-21 | 2009-06-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | 8-[3-Amino-Piperidin-1-YL]-Xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
UY28103A1 (es) * | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
US20060134206A1 (en) * | 2003-07-24 | 2006-06-22 | Iyer Eswaran K | Oral compositions for treatment of diseases |
US20070072810A1 (en) * | 2003-10-03 | 2007-03-29 | Takeda Pharmaceutical Company, Limited | Agent for treating diabetes |
PT1758905E (pt) * | 2004-02-18 | 2009-07-16 | Boehringer Ingelheim Int | 8-[3-amino-piperidin-1-il]-xantinas, sua preparação e sua utilização como inibidores de dpp-iv |
US7935723B2 (en) * | 2004-06-04 | 2011-05-03 | Novartis Pharma Ag | Use of organic compounds |
EP1782832A4 (en) * | 2004-08-26 | 2009-08-26 | Takeda Pharmaceutical | MEANS FOR THE TREATMENT OF DIABETES |
DE102004044221A1 (de) * | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
JP2009520763A (ja) * | 2005-12-23 | 2009-05-28 | ノバルティス アクチエンゲゼルシャフト | Dpp−iv阻害剤として有用な縮合ヘテロ環式化合物 |
WO2008017670A1 (en) * | 2006-08-08 | 2008-02-14 | Boehringer Ingelheim International Gmbh | Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
UY31291A1 (es) * | 2007-08-16 | 2009-03-31 | Composicion farmacéutica que comprende un derivado de pirazol-0-glucosido | |
CL2008002427A1 (es) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
WO2009037719A1 (en) * | 2007-09-21 | 2009-03-26 | Lupin Limited | Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors |
EP3646859A1 (en) * | 2009-11-27 | 2020-05-06 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
-
2009
- 2009-10-14 UY UY0001032177A patent/UY32177A/es not_active Application Discontinuation
- 2009-10-15 PE PE2011000893A patent/PE20110396A1/es not_active Application Discontinuation
- 2009-10-15 AR ARP090103973A patent/AR073876A1/es unknown
- 2009-10-15 KR KR1020247010795A patent/KR20240046643A/ko active Application Filing
- 2009-10-15 CA CA2738367A patent/CA2738367C/en active Active
- 2009-10-15 NZ NZ605207A patent/NZ605207A/en unknown
- 2009-10-15 CN CN201811589718.3A patent/CN109700814A/zh active Pending
- 2009-10-15 AU AU2009305419A patent/AU2009305419B2/en active Active
- 2009-10-15 KR KR1020207002692A patent/KR102427380B1/ko active IP Right Review Request
- 2009-10-15 TW TW098134981A patent/TWI520738B/zh active
- 2009-10-15 NZ NZ591996A patent/NZ591996A/xx unknown
- 2009-10-15 JP JP2011531494A patent/JP2012505859A/ja active Pending
- 2009-10-15 CN CN201810029286.4A patent/CN108042543A/zh active Pending
- 2009-10-15 WO PCT/EP2009/063511 patent/WO2010043688A1/en active Application Filing
- 2009-10-15 EA EA201100621A patent/EA026810B1/ru not_active IP Right Cessation
- 2009-10-15 MX MX2011003774A patent/MX2011003774A/es not_active Application Discontinuation
- 2009-10-15 KR KR1020227025908A patent/KR20220110860A/ko not_active Application Discontinuation
- 2009-10-15 US US13/124,196 patent/US20110275561A1/en not_active Abandoned
- 2009-10-15 EP EP09736932A patent/EP2349240A1/en not_active Withdrawn
- 2009-10-15 CN CN200980141002XA patent/CN102186466A/zh active Pending
- 2009-10-15 EP EP16195824.4A patent/EP3150204A3/en active Pending
- 2009-10-15 KR KR1020187009095A patent/KR20180035948A/ko active Application Filing
- 2009-10-15 KR KR1020177012224A patent/KR20170053742A/ko active Search and Examination
- 2009-10-15 KR KR1020117008561A patent/KR20110066936A/ko active Application Filing
-
2011
- 2011-02-23 IL IL211370A patent/IL211370A0/en unknown
- 2011-04-08 MX MX2020009811A patent/MX2020009811A/es unknown
- 2011-04-08 MX MX2022001797A patent/MX2022001797A/es unknown
- 2011-04-11 EC EC2011010971A patent/ECSP11010971A/es unknown
- 2011-04-13 MA MA33769A patent/MA32872B1/fr unknown
- 2011-04-14 TN TN2011000176A patent/TN2011000176A1/fr unknown
- 2011-04-19 CO CO11049233A patent/CO6361917A2/es not_active Application Discontinuation
-
2014
- 2014-02-28 JP JP2014039772A patent/JP6262023B2/ja active Active
-
2015
- 2015-11-12 US US14/939,169 patent/US20160058769A1/en not_active Abandoned
-
2016
- 2016-03-09 JP JP2016046077A patent/JP2016164161A/ja active Pending
-
2017
- 2017-09-08 US US15/698,696 patent/US20170368068A1/en not_active Abandoned
-
2018
- 2018-04-25 JP JP2018083792A patent/JP6811203B2/ja active Active
-
2022
- 2022-07-11 JP JP2022111237A patent/JP2022125360A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32177A (es) | Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético | |
EA201100335A1 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
CO6351714A2 (es) | Tratamiento para diabetes en pacientes inapropiados para terapia con metformina | |
MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
NZ603319A (en) | Diabetes therapy | |
CY1115350T1 (el) | Χρησεις αναστολεων της dpp iv | |
EA201101037A1 (ru) | Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином | |
MX2010004450A (es) | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. | |
PL385586A1 (pl) | Nowe analogi insuliny o przedłużonym działaniu | |
WO2009068659A3 (en) | Novel disease treatment by predicting drug association | |
AR086395A1 (es) | Envase para el tratamiento de patologias | |
BRPI0702847A (pt) | formas de dosagem unitária de temozolomida | |
AR048460A1 (es) | Tratamiento de la funcion respiratoria alterada con gaboxadol | |
UA106357C2 (ru) | Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль, несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством | |
UA35558U (ru) | Способ лечения кандидоза слизистой оболочки полости рта у больных сахарным диабетом | |
TN2011000060A1 (en) | Treatment for diabetes in patients inappropriate for metformin therapy | |
UA85523C2 (ru) | Применение n-стеароилэтаноламина в качестве лекарственного средства для терапии сахарного диабета і и іі типов | |
TH112187A (th) | การรักษาของเบาหวานในผู้ป่วยที่มีการควบคุมน้ำตาลในเลือดที่ไม่เพียงพอแม้จะรักษาด้วยยาต้านเบาหวานชนิดให้ทางปากหรือไม่ได้ให้ทางปาก | |
UA67555U (ru) | Способ профилактики повторного суицидального поведения в ранний постсуицидальный период | |
UA29556U (ru) | Способ лечения больных острыми вирусными менингитами | |
TH0901003547A (th) | การรักษาสำหรับโรคเบาหวานในคนไข้ที่ไม่เหมาะสำหรับการรักษาด้วยเมทฟอร์มิน | |
UA57509U (ru) | Способ лечения гипергомоцистеинурии у больных ишемической болезнью сердца c сопутствующим сахарным диабетом 2 типа | |
TH112187B (th) | การรักษาของเบาหวานในผู้ป่วยที่มีการควบคุมน้ำตาลในเลือดที่ไม่เพียงพอแม้จะรักษาด้วยยาต้านเบาหวานชนิดให้ทางปากหรือไม่ได้ให้ทางปาก |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20180919 |